As costs for basic testing rise and regulatory requirements become increasingly stringent, preclinical studies are taking longer, clinical trials are expanding in scale, failure rates in clinical trials are increasing, and drug development is shifting toward chronic and degenerative diseases, which demand greater time and financial investment. These multiple factors have led to a rapid increase in the cost of new drug development, placing pressure on pharmaceutical companies’ R&D efforts while simultaneously creating substantial market opportunities for CRO/CMO firms.
# The Market Space Is Huge, China Has Become a Major Country in Pharmaceutical Outsourcing Services
Moreover, the global pharmaceutical R&D outsourcing market continues to maintain double-digit growth, with the industry steadily shifting toward China. The Chinese market has sustained stable growth, driven by its strong capabilities in chemical synthesis development and manufacturing, thereby fostering numerous outstanding CRO/CMO companies. According to Informa data, the market size of China’s CMO industry was $2.2 billion in 2012 and is projected to reach $5 billion in 2017, representing a compound annual growth rate (CAGR) of 17.8%. As reported in PwC’s “Trends in Pharmaceutical R&D Outsourcing in Asia,” China has surpassed India to become the most favored destination for pharmaceutical outsourcing services in Asia, when comprehensively evaluating cost, risk, and market opportunities.
Challenges and Opportunities Go Hand in Hand: Technological Innovation Seizes the Initiative for Development
The CMO industry faces challenges alongside its development. Pharmaceutical companies expect CRO/CMO providers to leverage their manufacturing facilities and technical expertise to assume more innovative roles in process development and optimization, thereby helping pharmaceutical companies improve production processes, enhance synthesis efficiency, and ultimately reduce manufacturing costs. Therefore, high-value-added process development and industrial application represent the future trend of the pharmaceutical manufacturing industry.
Pharmaceutical CMO Innovators Convene by West Lake to Discuss Major Initiatives
Therefore, VCBeat will call for nominations for the “Most Innovative Pharmaceutical CMO Companies” in the pharmaceutical CMO sector. After screening, we will provide support to 10 of these pharmaceutical CMO companies.One Free Report Article。
Meanwhile, we will invite the registered enterprises to participate.November 10 in Hangzhou, co-hosted by VCBeat and China Fortune Land Development Co., Ltd., with the theme of“The Development Path of Pharmaceutical CMOs Amidst the Surge in Medical Innovation”Biopharmaceutical CMO Meet-and-Greet.

This event will bring together industry leaders from China’s pharmaceutical and medical device CMO sectors for an intimate salon-style discussion, featuring in-depth exploration, analysis, and exchange of perspectives. Participants will examine the current state of development, challenges, and opportunities in China’s pharmaceutical CMO industry; address key difficulties and pain points encountered during growth; and analyze policy directions and emerging trends. Against the backdrop of vigorous new drug R&D efforts, the discussion will focus on technological advancements and channel evolution within the pharmaceutical CMO landscape. Furthermore, the event aims to deepen understanding of complementary resources among enterprises, facilitating the translation of intellectual exchanges into tangible collaborations.
Event Time: November 10, 2018 (Saturday) 14:30-17:00
Venue: Shiliupu Coffee, No. 9 Baiyun Road, Shangcheng District, Hangzhou
This event is exclusively open to senior executives from companies in the pharmaceutical and medical device CMO sectors. Confirmed participating companies include:
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shenzhen Puruijin Biopharmaceutical Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
Laobaixing Pharmacy Group
Guangdong Raffles Pharmaceutical Technology Co., Ltd.
Shanghai Bowei Biopharmaceutical Co., Ltd.
New Drug Founders Club
Epo Biotechnology Co., Ltd.
Hangguan Guanzi Health Technology Co., Ltd.
Beijing DeepInsight Technology Co., Ltd.
Xiangrong (Shanghai) Biotechnology Co., Ltd.
Huanuotong (Beijing) Pharmaceutical Technology Co., Ltd.
Beijing Shiji Maijin Biotechnology Co., Ltd.
Hanteng Biologics
Jiangsu Sida Pharmaceutical Co., Ltd.
On November 10, by the West Lake, we have prepared a modest reception and await your esteemed presence.

Registration Link: http://t.cn/E7iLHea